Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Director | September 01, 2026 | September 03, 2026 |
| GRAIL, Inc.GRAL · Entity 4122 | Director · Chief Executive Officer | April 08, 2026 | April 09, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | SVP, Global Quality & Ops | February 17, 2021 | February 18, 2021 |
| Twist Bioscience CorpTWST · Entity 3619 | Director | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,686 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 5,686 · Balance 5,686 F1: Represents a restricted stock unit ("RSU") award. The RSUs vest in equal annual installments over 3 years measured from September 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.36 · Expires 2036-08-31 | Direct | 25,599 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 25,599 · Balance 25,599 F2: One-third of the shares subject to the option will vest on September 1, 2027 and the remainder of the shares subject to the grant will vest in equal monthly installments thereafter through September 1, 2029, subject to the reporting person's continuous service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs vest in equal annual installments over 3 years measured from September 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
F2: One-third of the shares subject to the option will vest on September 1, 2027 and the remainder of the shares subject to the grant will vest in equal monthly installments thereafter through September 1, 2029, subject to the reporting person's continuous service as of each such vesting date.
GRAIL, Inc.
Report date April 08, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 518,582 |
Reported balance
After 2026-04-08 transaction · row 1
1 source rowRow 1 · 2026-04-08 · Sale · Disposed 123,502 · Balance 518,582 F1: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price.
ILLUMINA, INC.
Report date February 17, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,617 |
Ending reported balance
After 2021-02-17 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-02-17 · Grant · Acquired 694 · Balance 6,489 F1: Represents additional shares of stock awarded as a result of the Company achieving at least 111% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Row 2 · 2021-02-17 · Exercise / conversion · Acquired 6,306 · Balance 12,795 F2: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Row 3 · 2021-02-17 · Tax withholding · Disposed 3,178 · Balance 9,617 |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2021-01-03 | Direct | 0 |
Reported balance
After 2021-02-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-02-17 · Exercise / conversion · Disposed 6,306 · Balance 0 F2: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents additional shares of stock awarded as a result of the Company achieving at least 111% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017.
F2: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017.
Twist Bioscience Corp
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,983 |
Reported balance
After 2026-02-05 transaction · row 1
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 5,095 · Balance 28,983 F1: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:27 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantStock Option (Right to Buy) · Derivative | 25,599 | $0.00 Strike: $29.36 | $0.00 |
DisclosureSEC source: 0001222644-26-000004 · form4-09032026_080949.xml · derivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,599 Underlying: Common Stock · 25,599 shares Expires 2036-08-31 F2 · derivative.exercise_date: One-third of the shares subject to the option will vest on September 1, 2027 and the remainder of the shares subject to the grant will vest in equal monthly installments thereafter through September 1, 2029, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:27 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantCommon Stock | 5,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001222644-26-000004 · form4-09032026_080949.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,686 F1 · kind: Represents a restricted stock unit ("RSU") award. The RSUs vest in equal annual installments over 3 years measured from September 1, 2026, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 08, 2026 Filed Apr 9, 2026 22:58 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 123,502 | $49.92 | $6,164,923.44 |
DisclosureSEC source: 0001628280-26-024550 · wk-form4_1775775497.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518,582 F1 · price: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 01:35 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 258 | $46.73 | $12,056.34 |
DisclosureSEC source: 0001628280-26-016216 · wk-form4_1773106552.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,084 F1 · price: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 01:35 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 7,203 | $47.93 | $345,239.79 |
DisclosureSEC source: 0001628280-26-016216 · wk-form4_1773106552.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,342 F1 · price: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 05, 2026 Filed Mar 10, 2026 01:35 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 980 | $53.01 | $51,949.80 |
DisclosureSEC source: 0001628280-26-016216 · wk-form4_1773106552.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 649,545 F1 · price: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:15 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 1,717 | $51.84 | $89,014.43 |
DisclosureSEC source: 0001628280-26-014311 · wk-form4_1772586949.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,525 F1 · price: Represents automatic sell-to-cover transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:15 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 35,787 | $50.09 | $1,792,402.63 |
DisclosureSEC source: 0001628280-26-014311 · wk-form4_1772586949.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,242 F1 · price: Represents automatic sell-to-cover transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 5,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-001343 · marketforms-72067.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,983 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:12 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 1,604 | $97.28 | $156,042.09 |
DisclosureSEC source: 0001628280-25-055599 · wk-form4_1764969148.xml · nonDerivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 688,029 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.89 to $97.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price within the range set forth in this footnote. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:12 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 8,233 | $96.22 | $792,152.09 |
DisclosureSEC source: 0001628280-25-055599 · wk-form4_1764969148.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,633 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.88 to $96.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price within the range set forth in this footnote. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:12 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 15,356 | $95.28 | $1,463,092.04 |
DisclosureSEC source: 0001628280-25-055599 · wk-form4_1764969148.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,866 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.79 to $95.7850 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price within the range set forth in this footnote. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:12 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 14,807 | $94.43 | $1,398,248.70 |
DisclosureSEC source: 0001628280-25-055599 · wk-form4_1764969148.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 713,222 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.78 to $94.7750 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price within the range set forth in this footnote. F2 · balance_after: Includes 641 shares acquired under the Company's ESPP purchased on November 14, 2025. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 22:18 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 7,239 | $68.88 | $498,622.32 |
DisclosureSEC source: 0001628280-25-045269 · wk-form4_1760653079.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,388 F1 · price: Represents automatic sell-to-cover transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:44 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 94,035 | $33.93 | $3,190,607.55 |
DisclosureSEC source: 0001699031-25-000099 · wk-form4_1746492275.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734,627 F1 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 11, 2025 Filed Apr 3, 2025 20:43 UTC Amendment | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 7,625 | $31.21 | $237,976.25 |
DisclosureSEC source: 0001699031-25-000066 · wk-form4a_1743713015.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,662 F1 · date: This amendment is filed to correct the date of the transaction reported in the original Form 4. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 07, 2025 Filed Mar 12, 2025 20:07 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 7,625 | $31.21 | $237,976.25 |
DisclosureSEC source: 0001699031-25-000059 · wk-form4_1741810047.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,662 F1 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:27 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 994 | $41.51 | $41,260.94 |
DisclosureSEC source: 0001699031-25-000049 · wk-form4_1741296428.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836,287 F1 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 4,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-002231 · marketforms-68036.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,888 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:19 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 224,620 | $28.84 | $6,478,040.80 |
DisclosureSEC source: 0001699031-25-000008 · wk-form4_1738707584.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,281 F1 · shares: Represents an award of 224,620 restricted stock units ("RSUs") which will vest in three substantially equal annual installments, beginning on February 28, 2026, subject to the awardee's continued service through such date. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs will be settled in common stock upon vesting. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 22:32 UTC | GRAIL, Inc. GRAL · Entity 4122 | SaleCommon Stock | 123,454 | $14.02 | $1,730,825.08 |
DisclosureSEC source: 0001628280-24-043069 · wk-form4_1729204370.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612,661 F1 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the Sell-To-Cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. Read SEC document |
| October 03, 2024 Filed Oct 8, 2024 00:36 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 45,840 | $12.57 | $576,208.80 |
DisclosureSEC source: 0001628280-24-042471 · wk-form4_1728347776.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 736,115 F2 · shares: Represents an award of 45,840 RSUs which will vest and become payable on October 3, 2026, subject to the awardee's continuing to be a service provider on such date. Read SEC document |
| October 03, 2024 Filed Oct 8, 2024 00:36 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 214,240 | $12.57 | $2,692,996.80 |
DisclosureSEC source: 0001628280-24-042471 · wk-form4_1728347776.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,275 F1 · shares: Represents an award of 214,240 restricted stock units ("RSUs") which will vest and become payable on April 3, 2026, subject to the awardee's continuing to be a service provider on such date. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs will be settled in common stock upon vesting. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:53 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 475,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-030869 · wk-form4_1719953574.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,035 F1 · date: On June 24, 2024, Illumina, Inc. (Illumina) completed a pro rata spin-off distribution (the Distribution) of 85.5% of the outstanding shares of the Issuer to the holders of record of Illumina common stock as of June 13, 2024 (the Record Date). In connection with the Distribution, pursuant to the terms of the Employee Matters Agreement, dated as of June 21, 2024, by and between Illumina and the Issuer (the EMA), all outstanding cash-based equity appreciation incentive awards held by the Reporting Person were equitably adjusted and converted into equity-based awards with respect to the common stock of the Issuer, with such equitable adjustments determined based on the value of the award at the time of the Distribution (determined in accordance with the EMA) compared to the market capitalization of the Issuer for the four trading days following the Distribution. F2 · shares: Represents the grant of restricted stock units (RSUs) of the Issuer upon the conversion of cash-based equity appreciation incentive awards held by the Reporting Person as of the Distribution in connection with the Distribution, in accordance with the terms of the EMA. The RSUs were granted pursuant to the GRAIL, Inc. 2024 Incentive Award Plan in a manner intended to preserve the aggregate intrinsic value of the underlying cash-based equity appreciation incentive awards, on generally the same terms and conditions as applied to the cash-based equity appreciation incentive awards prior to the Distribution (including vesting and payment schedules). F3 · shares: Includes (i) 242,974 RSUs that vest on October 14, 2024 (ii) 1,890 RSUs that vest on March 4, 2025, (iii) 14,006 RSUs that vest on March 6, 2025, (iv) 172,235 RSUs that vest on April 30, 2025, (v) 14,170 RSUs that vest on October 14, 2025 (vi) 1,891 RSUs that vest on March 4, 2026, (vii) 14,006 RSUs that vest on March 6, 2026 and (viii) 14,006 RSUs that vest on March 6, 2027. Each RSU represents the right to receive, at settlement upon vesting, one share of common stock. F4 · balance_after: Includes 857 shares of the common stock of the Issuer received in connection with the Distribution in respect of Illumina common stock held as of the Record Date. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 21:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 5,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-002247 · marketforms-64641.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,416 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:15 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 8,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001882 · marketforms-59388.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,601 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 3,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-002206 · marketforms-55362.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,389 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 10,588 | $0.00 Strike: $30.41 | $0.00 |
DisclosureSEC source: 0001214659-21-002803 · marketforms-51731.xml · derivative · entry 5 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,588 shares Expires 2029-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option vested and became exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,770 | $134.04 | $237,255.05 |
DisclosureSEC source: 0001214659-21-002803 · marketforms-51731.xml · nonDerivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $133.61 to $134.47 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,519 | $133.10 | $867,665.86 |
DisclosureSEC source: 0001214659-21-002803 · marketforms-51731.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,668 F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.59 to $133.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,299 | $132.15 | $303,824.12 |
DisclosureSEC source: 0001214659-21-002803 · marketforms-51731.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,187 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.44 to $132.37 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 10,588 | $30.41 | $321,981.08 |
DisclosureSEC source: 0001214659-21-002803 · marketforms-51731.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:49 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 6,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006523 · form4.xml · derivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,306 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. F2 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:49 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 3,178 | $494.24 | $1,570,694.72 |
DisclosureSEC source: 0001127602-21-006523 · form4.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,617 Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:49 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 6,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006523 · form4.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:49 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 694 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006523 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,489 F1 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 111% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005285 · form4.xml · derivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,967 Underlying: Common Stock · 4,967 shares Expires 2023-12-31 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005285 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,795 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2021, November 5, 2022, November 5, 2023, and November 5, 2024, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: Balance includes 47 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 973 | $0.00 Strike: $189.96 | $0.00 |
DisclosureSEC source: 0001214659-21-001432 · marketforms-51434.xml · derivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973 Underlying: Common Stock · 973 shares Expires 2031-02-02 F3 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 486 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-001432 · marketforms-51434.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 F1 · shares: Represents a restricted stock unit award (the "RSU Award") of which 100% vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 50 | $319.50 | $15,975.00 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 8 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,092 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 120 | $318.83 | $38,259.60 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 7 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,142 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F7 · price: Weighted average sale price representing 120 shares sold ranging from $318.39 to $319.37 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 834 | $317.44 | $264,744.96 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 6 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,262 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F6 · price: Weighted average sale price representing 834 shares sold ranging from $317.12 to $318.02 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 150 | $315.76 | $47,364.00 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 5 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F5 · price: Weighted average sale price representing 150 shares sold ranging from $315.28 to $316 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 580 | $314.74 | $182,549.20 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,246 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 580 shares sold ranging from $314.25 to $315.21 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 50 | $313.13 | $15,656.50 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,826 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 926 | $312.35 | $289,236.10 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,876 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 926 shares sold ranging from $312.01 to $312.85 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 180 | $311.34 | $56,041.20 |
DisclosureSEC source: 0001127602-20-030334 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,802 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 180 shares sold ranging from $311 to $311.99 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:42 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,121 | $311.72 | $349,438.12 |
DisclosureSEC source: 0001127602-20-028501 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,982 Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 23:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 633 | $357.63 | $226,382.39 |
DisclosureSEC source: 0001127602-20-024654 · form4.xml · nonDerivative · entry 5 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,103 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F7 · price: Weighted average sale price representing 633 shares sold ranging from $357.23 to $358.105 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Canc Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.